A wealth of experience is at the core of Saol
As CEO of Saol since April 2016, Dave’s career includes time on the executive management team as Vice President, Commercial Operations at Corcept Therapeutics, a leader in the discovery and development of cortisol-related drugs.
Leadership roles at Genentech enabled him to gain experience in biotechnology and genome sequencing. Prior to Genentech, Dave served in roles at The Broad Institute and Intel Corporation. His wish to improve patient lives led him to co-found Articulate Technologies, a company that provides treatment options for patients living with speech and communication disorders.
Dave holds a Bachelor of Science degree in Engineering from Northwestern University, as well as Master of Science and Master of Business Administration degrees from the Massachusetts Institute of Technology. He completed his post-graduate studies at Stanford University and has performed research at Harvard Medical School.
Sharon Hamm, Pharm.D., RPH
Sharon’s background incorporates more than 30 years of experience encompassing non-clinical, clinical, pharmaceutical development, quality, compliance, pharmacovigilance, and regulatory affairs. She has lent her expertise to a diverse range of therapeutic areas.
Following 19 years with Elan Corporation where she last served as the Senior Vice President, Technical Operations, Sharon became an independent consultant to support clients in all stages of pre and post-market development, including product assessment, development planning, and regulatory support. She also held management roles in Regulatory and Compliance at Solvay Pharmaceuticals.
Sharon holds both Bachelor and Doctor of Pharmacy degrees from Mercer University College of Pharmacy.
Paul joined Saol in 2017 as Vice President of Supply Chain, in addition to assuming the role of General Manager of Saol Therapeutics Research Limited based in Ireland.
His background includes 15 years of experience in global supply chain optimization, strategic planning and project leadership in both the consumer goods and pharmaceutical industries. Prior to Saol, Paul served on the leadership team of Astellas Pharma's European Pharmaceutical Technology Division, heading up the strategic business planning department. During his 9 years with Astellas he developed a highly-successful, multi-cultural team responsible for leading global and regional strategic projects. He was the leader of the program to introduce new pharmaceutical supply chains for Russia and the CIS countries and delivered several supply chain optimization projects, as well as developed mid-term strategies for manufacturing sites based across Europe. Prior to Astellas, Paul held roles at SAP and Mondi Paper.
Paul holds degrees in Civil Engineering and Business Systems, INSEAD Leadership development certificates and a Master of Business Administration degree from UCD Michael Smurfit Business School.
Focusing primarily on healthcare and pharmaceutical companies, Brian has accumulated 16 years of finance and accounting expertise, including most recently as the Director of Finance for Vidara Therapeutics, an Ireland-based specialty pharmaceutical company that he helped found. In this role, he coordinated a successful reverse merger with Horizon Pharma in 2014. In addition, Brian held roles with Northside Hospital, Alaven Pharmaceutical, Deliotte, and Arthur Andersen.
Brian received his Master of Accountancy and Bachelor of Science in Accounting degrees from the University of Alabama. He is a registered CPA in the state of Georgia and a member of the American Institute of Certified Public Accountants (AICPA).
Throughout Melinda’s 15 plus years in the pharmaceutical industry, she headed up Human Resources and Operations and served as the Compliance Officer for Vidara Therapeutics, a specialty pharmaceutical company, where she was instrumental in building and managing a high performing senior clinical field team while building the company’s compliance program.
After the merger of Vidara with Horizon Pharma, Melinda continued with the company to support the full and successful integration of the two companies and the additional growth of the orphan business unit.
Prior to Vidara, Melinda held roles at Meda Pharmaceuticals, Alaven Pharmaceuticals and Wyeth.
Melinda holds a Master’s degree in Human Resources from College of St. Elizabeth and a Bachelor degree in Social Work from West Chester University.
Scott has 20 years of experience in sales and sales leadership in the pharmaceutical and medical device industries with an expertise in product launch and the healthcare promotion of innovative medicines and treatments. Prior to joining Saol, he excelled at Horizon Pharma (Vidara Therapeutics) as a member of the orphan drug business unit responsible for the commercial re-launch of Actimmune. Prior to that, he served in various sales leadership roles at US Endoscopy (a subsidiary of Steris), from gastroenterology product specialist to regional sales manager to business development specialist for the organization’s start-up urology division.
Scott started his pharmaceutical career as a sales representative for GlaxoSmithKline, working his way up to senior district sales manager.
Scott holds a Bachelor of Journalism degree from the University of Missouri-Columbia.